Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acute leukemia in children

C H Pui1

  • 1St. Jude Children's Research Hospital, Memphis, TN 38105, USA.

Current Opinion in Hematology
|July 1, 1996
PubMed
Summary
This summary is machine-generated.

Molecular characterization improves leukemia diagnosis and treatment. Genetic information guides therapy for acute lymphoblastic leukemia and acute myeloid leukemia, personalizing patient care.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pre-B-Cell Acute Lymphoblastic Leukemia in Childhood.

Leukemia & lymphoma·2016
Same author

A revised definition for cure of childhood acute lymphoblastic leukemia.

Leukemia·2014
Same author

Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase.

Cancer chemotherapy and pharmacology·2014
Same author

Calcium and cholecalciferol supplementation provides no added benefit to nutritional counseling to improve bone mineral density in survivors of childhood acute lymphoblastic leukemia (ALL).

Pediatric blood & cancer·2014
Same author

Results of treatment of advanced-stage lymphoblastic lymphoma at St Jude Children's Research Hospital from 1962 to 2002.

Annals of oncology : official journal of the European Society for Medical Oncology·2013
Same author

Cognitive outcomes following contemporary treatment without cranial irradiation for childhood acute lymphoblastic leukemia.

Journal of the National Cancer Institute·2012
Same journal

Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential.

Current opinion in hematology·2026
Same journal

Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.

Current opinion in hematology·2026
Same journal

Nutrition as a regulator of hematopoietic stem cell biology and transplantation.

Current opinion in hematology·2026
Same journal

From biomimicry to clinical actionability: rethinking high-shear thrombosis as a mechanobiological system.

Current opinion in hematology·2026
Same journal

Bidirectional relationship between metabolic and thrombotic disease mechanisms.

Current opinion in hematology·2026
Same journal

The dual role of the brain-derived neurotrophic factor as a regulator of hemostasis and thrombotic risk.

Current opinion in hematology·2026
See all related articles

Area of Science:

  • Hematology
  • Molecular Biology
  • Pediatric Oncology

Background:

  • Molecular characterization of leukemic cells enhances diagnosis, treatment assignment, and residual disease monitoring in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).
  • Specific genetic rearrangements are identified in up to 50% of pediatric ALL and AML cases.
  • Key genes like p16 (MTS1) and TEL/AML1 are recognized in childhood ALL.

Purpose of the Study:

  • To highlight the increasing reliance on genetic information for guiding treatment decisions in acute leukemias.
  • To discuss current and emerging therapeutic strategies based on specific genetic subtypes.
  • To emphasize the need for protocol-based studies to identify targeted treatments for genetically defined leukemias.

Main Methods:

Related Experiment Videos

  • Review of current molecular diagnostic techniques in leukemia.
  • Analysis of genetic rearrangements and their correlation with treatment protocols.
  • Examination of therapeutic strategies tailored to specific genetic profiles in ALL and AML.

    • Main Results:

    • Genetic information is crucial for treatment selection, including stem cell transplantation for BCR-ABL or MLL rearrangements in ALL and monosomy 7 in AML.
    • Antimetabolite therapy is used for hyperdiploid ALL (DNA index > or = 1.16).
    • Retinoic acid and anthracyclines are key for acute promyelocytic AML with PML-RARA fusion.

    Conclusions:

    • Genetic profiling is transforming leukemia treatment, enabling personalized therapeutic approaches.
    • Future research should focus on identifying specific treatments for other genetically defined leukemia subtypes.
    • Protocol-based studies with uniform risk criteria are essential for advancing leukemia therapy.